Literature DB >> 24462877

Atrial natriuretic peptide inhibits lipopolysaccharide-induced acute lung injury.

Takashi Nojiri1, Hiroshi Hosoda2, Takeshi Tokudome3, Koichi Miura2, Shin Ishikane3, Toru Kimura4, Yasushi Shintani4, Masayoshi Inoue4, Noriyoshi Sawabata4, Mikiya Miyazato3, Meinoshin Okumura4, Kenji Kangawa3.   

Abstract

OBJECTIVES: We recently reported that administration of atrial natriuretic peptide during the perioperative period has prophylactic effects with respect to not only cardiovascular but also respiratory complications following pulmonary resection. However, its mechanisms are not well understood. The objective of the present study was to investigate the mechanism of the prophylactic effects of atrial natriuretic peptide in an acute lung injury model.
METHODS: For the evaluation of the early phase of pulmonary inflammation, in vitro and in vivo studies using lipopolysaccharide were used. In the in vitro study, the effects of atrial natriuretic peptide on the induction of E-selectin by lipopolysaccharide in human pulmonary artery endothelial cells were evaluated. In the in vivo study, the effects of atrial natriuretic peptide on lipopolysaccharide-induced inflammatory cell infiltration and cytokine levels including tumor necrosis factor-alpha and interleukin-6 in the bronchoalveolar lavage fluid in the lungs of C57/B6 mice were examined. The number of myeloperoxidase-positive staining cells in the tissue sections of the lung of lipopolysaccharide-administered C57/B6 mice was also evaluated.
RESULTS: Atrial natriuretic peptide significantly attenuated the up-regulation of E-selectin expression induced by lipopolysaccharide in human pulmonary artery endothelial cells. There were significantly lower cell counts and levels of tumor necrosis factor-alpha and interleukin-6 in the bronchoalveolar lavage fluid of atrial natriuretic peptide-treated mice compared to control mice after lipopolysaccharide injection. In addition, there were significantly fewer myeloperoxidase-positive cells in atrial natriuretic peptide-treated mice than in control mice after lipopolysaccharide injection.
CONCLUSIONS: Atrial natriuretic peptide had a protective effect in the lipopolysaccharide-induced acute lung injury model. Atrial natriuretic peptide may be of value in therapeutic strategies aimed at the treatment of acute lung injury such as pneumonia or acute respiratory distress syndrome.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute lung injury; Atrial natriuretic peptide; Pulmonary inflammation

Mesh:

Substances:

Year:  2014        PMID: 24462877     DOI: 10.1016/j.pupt.2014.01.003

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  12 in total

1.  Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.

Authors:  Iuliia Polina; Mark Domondon; Rebecca Fox; Anastasia V Sudarikova; Miguel Troncoso; Valeriia Y Vasileva; Yuliia Kashyrina; Monika Beck Gooz; Ryan S Schibalski; Kristine Y DeLeon-Pennell; Wayne R Fitzgibbon; Daria V Ilatovskaya
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-28

Review 2.  Postperfusion lung syndrome: physiopathology and therapeutic options.

Authors:  Shi-Min Yuan
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jul-Sep

3.  Role of IL-1β in experimental cystic fibrosis upon P. aeruginosa infection.

Authors:  Jennifer Palomo; Tiffany Marchiol; Julie Piotet; Louis Fauconnier; Marieke Robinet; Flora Reverchon; Marc Le Bert; Dieudonnée Togbe; Ruvalic Buijs-Offerman; Marta Stolarczyk; Valérie F J Quesniaux; Bob J Scholte; Bernhard Ryffel
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

4.  C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice.

Authors:  Toru Kimura; Takashi Nojiri; Jun Hino; Hiroshi Hosoda; Koichi Miura; Yasushi Shintani; Masayoshi Inoue; Masahiro Zenitani; Hiroyuki Takabatake; Mikiya Miyazato; Meinoshin Okumura; Kenji Kangawa
Journal:  Respir Res       Date:  2016-02-19

5.  Veronicastrum axillare Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Suppression of Proinflammatory Mediators and Downregulation of the NF-κB Signaling Pathway.

Authors:  Quanxin Ma; Kai Wang; Qinqin Yang; Shun Ping; Weichun Zhao; Qiyang Shou; Weimin Zhou; Minli Chen
Journal:  Mediators Inflamm       Date:  2016-11-06       Impact factor: 4.711

6.  Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice : ANP for pulmonary fibrosis.

Authors:  Atsuko Okamoto; Takashi Nojiri; Kazuhisa Konishi; Takeshi Tokudome; Koichi Miura; Hiroshi Hosoda; Jun Hino; Mikiya Miyazato; Yohkoh Kyomoto; Kazuhisa Asai; Kazuto Hirata; Kenji Kangawa
Journal:  Respir Res       Date:  2017-01-03

7.  A Novel Small Peptide Inhibitor of NFκB, RH10, Blocks Oxidative Stress-Dependent Phenotypes in Cancer.

Authors:  Jessica Gambardella; Michele Ciccarelli; Carmine Del Giudice; Antonella Fiordelisi; Matteo De Rosa; Marina Sala; Roberto Pacelli; Pietro Campiglia; Bruno Trimarco; Guido Iaccarino; Daniela Sorriento
Journal:  Oxid Med Cell Longev       Date:  2018-11-04       Impact factor: 6.543

Review 8.  Peptide-Based Treatment: A Promising Cancer Therapy.

Authors:  Yu-Feng Xiao; Meng-Meng Jie; Bo-Sheng Li; Chang-Jiang Hu; Rui Xie; Bo Tang; Shi-Ming Yang
Journal:  J Immunol Res       Date:  2015-10-19       Impact factor: 4.818

9.  Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers.

Authors:  Takashi Nojiri; Miki Arai; Yutaka Suzuki; Motofumi Kumazoe; Takeshi Tokudome; Koichi Miura; Jun Hino; Hiroshi Hosoda; Mikiya Miyazato; Meinoshin Okumura; Shinpei Kawaoka; Kenji Kangawa
Journal:  Oncotarget       Date:  2017-05-25

Review 10.  The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.

Authors:  Alessandro Bellis; Ciro Mauro; Emanuele Barbato; Bruno Trimarco; Carmine Morisco
Journal:  Int J Mol Sci       Date:  2020-11-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.